Stock Information
Celldex Therapeutics Inc (CLDX)
Ticker Symbol: CLDX
Exchange: NASDAQ
Sector: N/A
Market Cap: $1,818.21 mil
Piotroski score: 2
PE Ratio: N/A
EPS (TTM): -3.3818
Revenue (TTM): $0.04 M
Dividend Yield: N/A%
ROE: -33.22%
Latest News
-
Stifel Reiterates Buy on Celldex Therapeutics, Raises Price Target to $68
Thu, Feb 26, 2026 10:19 AM
-
Celldex Therapeutics Q4 EPS $(1.22) Misses $(1.00) Estimate, Sales $100.000K Miss $1.477M Estimate
Wed, Feb 25, 2026 5:47 PM
-
Celldex Therapeutics shares are trading higher after the company announced the enrollment in its global Phase 3 program of barzolvolimab in chronic spontaneous urticaria.
Wed, Feb 25, 2026 12:00 PM
-
Celldex Completes Enrollment In Global Phase 3 Program Of Barzolvolimab In Chronic Spontaneous Urticaria, Which Consists Of Two Phase 3 Trials, EMBARQ-CSU1 And EMBARQ-CSU2
Wed, Feb 25, 2026 8:04 AM
Key Financials
Financial data not available
